Literature DB >> 21295739

Osteoporosis update from the 2010 santa fe bone symposium.

E Michael Lewiecki1, John P Bilezikian, Sundeep Khosla, Robert Marcus, Michael R McClung, Paul D Miller, Nelson B Watts, Michael Maricic.   

Abstract

The 11th Santa Fe Bone Symposium was held in Santa Fe, NM, USA, on August 6-7, 2010. This annual event addresses clinically relevant advances in the fields of osteoporosis and metabolic bone disease. The venue includes plenary presentations by internationally recognized experts, oral presentations of abstracts, and interactive panel discussions of challenging cases and controversial issues. Attendees are active participants throughout the symposium program. Topics for the 2010 symposium included potential applications of novel technologies for the assessment of skeletal health for research and clinical practice; new and emerging treatments for osteoporosis; appropriate use of pharmacological agents to prevent osteoporosis; controversies with bisphosphonate therapy; practical applications of the World Health Organization fracture risk assessment tool (FRAX; World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK); insights into the use of osteoanabolic agents to enhance fracture healing; and challenges in laboratory testing in the assessment of factors contributing to skeletal fragility. Concurrent sessions focused on critical thinking for technologists in the acquisition and analysis of data with dual-energy X-ray absorptiometry. The key messages from each presentation, including the best available medical evidence and potential current and future clinical applications, are provided here.
Copyright © 2011 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295739     DOI: 10.1016/j.jocd.2010.12.001

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  2 in total

1.  Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey.

Authors:  Nese Olmez Sarikaya; Secil Kapar Yavasi; Gulten Tan; Servet Satiroglu; Arife Hilal Yildiz; Bengi Oz; Ozlem Yoleri; Asuman Memis
Journal:  Clin Rheumatol       Date:  2014-01-29       Impact factor: 2.980

2.  Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drug Healthc Patient Saf       Date:  2011-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.